CAMBRIDGE, Mass., May 23, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: BIO International Convention Corporate […]
CAMBRIDGE, Mass., April 18, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 […]
Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology Collaboration enables Editas Medicine to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers CAMBRIDGE, Mass., April 3, 2019 – Editas Medicine, Inc. (Nasdaq: […]
Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs CAMBRIDGE, Mass., March 18, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment […]
CAMBRIDGE, Mass., March 5, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics, will present at the Cowen and Company […]
Dr. Bruce Blazar brings a wealth of knowledge as a leader in transplantation and immunobiology Dr. Courtney Crane brings key expertise in myeloid cell biology and genetic engineering CAMBRIDGE, Mass., Jan. 16, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel […]
CAMBRIDGE, Mass., Jan. 2, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare […]
CAMBRIDGE, Mass., Dec. 6, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, announced today the strengthening of its ongoing strategic collaboration with the McEwen Stem Cell Institute at the University Health […]
CAMBRIDGE, Mass., Nov. 26, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment of Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer. In her new role, […]
CAMBRIDGE, Mass., Nov. 7, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: American Heart […]
